DRUG
liraglutide 3.0 mg
Patients will be treated with commercially available Saxenda® prescribed according to routine clinical practice at the discretion of the treating physician.
Status
Completed
Phase
Not applicable
Enrollment
27
Locations
14
Results
Not posted
Publications
0
Study summary
This trial is conducted in North America. The aim is to investigate timely detection of pancreatitis cases as well as cases of suspicion of serious and non-serious adverse reactions possibly or probably related to Saxenda® in Mexican patients.
Interventions
DRUG
Patients will be treated with commercially available Saxenda® prescribed according to routine clinical practice at the discretion of the treating physician.
Timeline
First posted
May 16, 2016
Study start
May 16, 2016
Primary completion
Nov 30, 2021
Study completion
Feb 28, 2022
Results posted
Not reported
Registry updated
Apr 13, 2026
Outcomes
Frequency of pancreatitis
Time frame · Year 0-3
Adverse drug reactions (ADR)
Time frame · Year 0-3
Eligibility
Inclusion Criteria: * Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol) * The decision to initiate the treatment with commercially available Saxenda® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study * Obese patients (BMI equal to or above 30 kg/m\^2) or overweight patients (BMI Equal to or above 27 kg/m\^2) with at least one weight related comorbidity according to Saxenda® label text in Mexico * Age equal or above 18 years at the time of signing informed consent Exclusion Criteria: * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * Hypersensitivity to Saxenda® or to any of its excipients * Females of child-bearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice) * Diagnosis of type 1 diabetes
Study locations
Mexico. Showing up to 24 locations stored in the fast local snapshot.
Especialidades Médicas del Bosque
Guadalajara, Jalisco, Mexico
Investigación Clínica Especializada, S.C.
Guadalajara, Jalisco, Mexico
Centro de Investigacion Clinica Endocrinologica de Jalisco
Guadalajara, Jalisco, Mexico
Unidad Médica Dentistas
Guadalajara, Jalisco, Mexico
Hospital Bite Medica
Mexico City, México, D.F., Mexico
Hospital San Angel Inn
Mexico City, México, D.F., Mexico
Hospital HMG Coyoacan
Mexico City, México, D.F., Mexico
Hospital San Angel Inn_Mexico City
Mexico City, México, D.F., Mexico
Torre Médica Dalinde
Mexico City, México, D.F., Mexico
Zrii de México Ejecutivo Independiente
Monterrey, Nuevo León, Mexico
Hospital CIMA Hermosillo
Hermosillo, Sonora, Mexico
Hospital Angeles de las Lomas
México, State of Mexico, Mexico
Medica Sur
Mexico City, Mexico
Hospital Angeles de Puebla
Puebla City, Mexico
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease
Phase 4
Recruiting
120
2026-07
4Moving Biotech · Knee Osteoarthritis · Synovitis of Knee
Phase 2
Active, not recruiting
129
2026-07
Ohio State University · Obesity & Overweight · Diabetes (DM)
Not applicable
Recruiting
300
2026-07
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Type 2 Diabetes Mellitus · Mild Cognitive Impairment
Not applicable
Completed
396
2026-07
Phase 1
Recruiting
71
2026-07
Novo Nordisk · Obesity
Phase 3
Active, not recruiting
78
2026-07
West China Hospital · Alzheimer Disease · Diabetes Mellitus Type 2
Not applicable
Completed
213,891
2026-07
Indiana University · Obesity
Not applicable
Enrolling by invitation
125,000
2026-06
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.